Efficacy and Safety Study of Fentanyl Transdermal (Fentanest®)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Eligible patients who agree to participate will migrate from oral opioids to transdermal
patches and be followed for four weeks. Oral morphine will be provided as pain rescue
medication. The patients will inform the adverse events and rescue medication consumption.
The number of Fentanest® patches will be adjusted every visit aiming to reduce the rescue
medication consumption and adverse events to a minimum. The WHO-QOL- bref (quality of life
questionary) will be filled before and after the use of Fentanest®. Patients showing benefit
are eligible to a 3 weeks compassionate study.